Literature DB >> 25563493

Cervical cancer stem cells: opportunities and challenges.

Ravindresh Chhabra1.   

Abstract

INTRODUCTION: Cervical cancer remains a leading cause of cancer-related deaths in women in spite of screening and vaccination programs. The current treatment strategies including chemotherapy and surgery could only prolong the patient's survival rather than provide a permanent cure. In case of advanced cervical cancer, radical surgery remains the only option which not only affects the child-bearing ability of the patient, but also comes with a continual risk of recurrence of the disease. Hence, there is a need to develop innovative therapeutics. The cancer stem cell hypothesis states that a tumor has a hierarchical cellular structure in which only a small subpopulation, referred to as cancer stem cells (CSCs), is capable of tumorigenesis. The CSCs possess the stem-like properties of self-renewal and can differentiate into non-stem tumor cells.
RESULTS: A large number of studies suggest that CSCs are resistant to the conventional therapies used for cancer treatment. These therapies rather enrich the proportion of CSCs in the tumor by eliminating non-stem tumor cells, thereby causing enhanced drug resistance resulting in relapse of the disease. This makes CSCs as the most likely targets for therapeutic intervention. Also, the increase in the proportion of CSCs in patient samples is associated with poor survival rate, thus highlighting their potential role as prognostic biomarker.
CONCLUSION: The CSCs have been identified and characterized in cervical cancer cell lines, but there are hardly any reports of CSCs in cervical cancer patient samples. This review highlights the current status of research on cervical CSCs, their clinical significance and the challenges in the field.

Entities:  

Keywords:  CD49f; CSC; Cancer therapeutics; SOX2

Mesh:

Substances:

Year:  2015        PMID: 25563493     DOI: 10.1007/s00432-014-1905-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  86 in total

1.  Core transcriptional regulatory circuitry in human embryonic stem cells.

Authors:  Laurie A Boyer; Tong Ihn Lee; Megan F Cole; Sarah E Johnstone; Stuart S Levine; Jacob P Zucker; Matthew G Guenther; Roshan M Kumar; Heather L Murray; Richard G Jenner; David K Gifford; Douglas A Melton; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2005-09-23       Impact factor: 41.582

Review 2.  Cancer stem cells: mirage or reality?

Authors:  Piyush B Gupta; Christine L Chaffer; Robert A Weinberg
Journal:  Nat Med       Date:  2009-09-04       Impact factor: 53.440

3.  Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma.

Authors:  Ayami Sasaki; Toshiya Kamiyama; Hideki Yokoo; Kazuaki Nakanishi; Kanako Kubota; Hironori Haga; Michiaki Matsushita; Michitaka Ozaki; Yoshihiro Matsuno; Satoru Todo
Journal:  Oncol Rep       Date:  2010-08       Impact factor: 3.906

4.  Expression of the p53 homologue p63 in early cervical neoplasia.

Authors:  B J Quade; A Yang; Y Wang; D Sun; J Park; E E Sheets; A Cviko; J M Federschneider; R Peters; F D McKeon; C P Crum
Journal:  Gynecol Oncol       Date:  2001-01       Impact factor: 5.482

Review 5.  Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.

Authors:  T C Pomfret; J M Gagnon; A T Gilchrist
Journal:  J Clin Pharm Ther       Date:  2011-02       Impact factor: 2.512

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 7.  Vaccines against cervical cancer.

Authors:  Linda J Rogers; Lois J Eva; David Michael Luesley
Journal:  Curr Opin Oncol       Date:  2008-09       Impact factor: 3.645

8.  The expression of ALDH1 in cervical carcinoma.

Authors:  Tingting Yao; Qing Chen; Bingzhong Zhang; Hui Zhou; Zhongqiu Lin
Journal:  Med Sci Monit       Date:  2011-08

9.  Cervical cancer cells with positive Sox2 expression exhibit the properties of cancer stem cells.

Authors:  Xiao-Fang Liu; Wen-Ting Yang; Rui Xu; Jun-Tian Liu; Peng-Sheng Zheng
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines.

Authors:  Ping Wang; Quanli Gao; Zhenhe Suo; Else Munthe; Steinar Solberg; Liwei Ma; Mengyu Wang; Nomdo Anton Christiaan Westerdaal; Gunnar Kvalheim; Gustav Gaudernack
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more
  15 in total

Review 1.  Cancer stem cells and evolving novel therapies: a paradigm shift.

Authors:  Sangeetha Vasudevaraj Naveen; Kumar Kalaivani
Journal:  Stem Cell Investig       Date:  2018-01-23

Review 2.  Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer.

Authors:  Niyati Sudhalkar; Nidul P Rathod; Ashwathi Mathews; Supriya Chopra; Harshini Sriram; Shyam K Shrivastava; Jayant S Goda
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-08

3.  Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.

Authors:  Eriko Yokoi; Seiji Mabuchi; Kotaro Shimura; Naoko Komura; Katsumi Kozasa; Hiromasa Kuroda; Ryoko Takahashi; Tomoyuki Sasano; Mahiru Kawano; Yuri Matsumoto; Michiko Kodama; Kae Hashimoto; Kenjiro Sawada; Tadashi Kimura
Journal:  Invest New Drugs       Date:  2018-10-30       Impact factor: 3.850

4.  Cervical cancer stem cells manifest radioresistance: Association with upregulated AP-1 activity.

Authors:  Abhishek Tyagi; Kanchan Vishnoi; Harsimrut Kaur; Yogesh Srivastava; Bal Gangadhar Roy; Bhudev C Das; Alok C Bharti
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

5.  MiR-23b controls ALDH1A1 expression in cervical cancer stem cells.

Authors:  Weiwen Wang; Yang Li; Na Liu; Yu Gao; Long Li
Journal:  BMC Cancer       Date:  2017-04-27       Impact factor: 4.430

6.  LncRNA HOTAIR promotes proliferation and inhibits apoptosis by sponging miR-214-3p in HPV16 positive cervical cancer cells.

Authors:  Yu Zhou; Yuqing Wang; Mingying Lin; Daiqian Wu; Min Zhao
Journal:  Cancer Cell Int       Date:  2021-07-28       Impact factor: 5.722

7.  A1E reduces stemness and self-renewal in HPV 16-positive cervical cancer stem cells.

Authors:  Taeho Kwon; Yesol Bak; Sun-Young Ham; Dae-Yeul Yu; Do-Young Yoon
Journal:  BMC Complement Altern Med       Date:  2016-02-02       Impact factor: 3.659

8.  Investigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing data.

Authors:  Cheng-Wei Li; Bor-Sen Chen
Journal:  Cell Cycle       Date:  2016-06-13       Impact factor: 4.534

9.  let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer.

Authors:  Ravindresh Chhabra
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

10.  Upregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinoma.

Authors:  Wuniqiemu Tulake; Reziwanguli Yuemaier; Lei Sheng; Mingfang Ru; Dilare Lidifu; Abulizi Abudula
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.